This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

This study has been completed.
Information provided by:
University of Pennsylvania Identifier:
First received: April 13, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.

Condition Intervention
Warfarin and NSAID Behavioral: Electronic Alert

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Official Title: The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Decreased rate of prescription of the combination of warfarin and NSAID [ Time Frame: 17 months ]

Enrollment: 1865
Study Start Date: August 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
Behavioral: Electronic Alert
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All

Inclusion Criteria:

  • All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00880932

United States, Pennsylvania
Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center
Phila, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
  More Information

Responsible Party: UPenn School of Medicine Identifier: NCT00880932     History of Changes
Other Study ID Numbers: 803787
Study First Received: April 13, 2009
Last Updated: April 13, 2009

Keywords provided by University of Pennsylvania:
The condition is the concomitant prescription of

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on August 18, 2017